Hudson Bay Capital Management
AXSM icon

Hudson Bay Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Hudson Bay Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
43,020
+27,800
+183% +$6.03M 0.03% 353
2026
Q1 		$2.57M Buy
+15,220
New +$2.63M 0.01% 699
2025
Q3 		– Sell
-25,037
Closed -$2.61M – 1256
2025
Q2 		$2.61M Buy
+25,037
New +$2.65M 0.01% 726
2025
Q1 		– Sell
-12,500
Closed -$1.06M – 1305
2024
Q4 		$1.06M Buy
+12,500
New +$1.15M ﹤0.01% 737

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hudson Bay Capital Management's AXSM Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Axsome Therapeutics (AXSM) stake by 183% in Q2 2026, buying an estimated $6.03M and bringing the position to 43,020 shares worth $10.5M. The position accounts for 0.03% of the portfolio, ranked #353.

Hudson Bay Capital Management first reported a position in AXSM in Q4 2024 and has held it in 4 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Hudson Bay Capital Management held 43,020 shares of Axsome Therapeutics worth $10.5M as of Q2 2026.
  • Hudson Bay Capital Management bought 27,800 Axsome Therapeutics shares in Q2 2026, an estimated $6.03M.
  • Axsome Therapeutics made up 0.03% of Hudson Bay Capital Management's portfolio in Q2 2026, its #353 holding.
  • Hudson Bay Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.